Pentoxifylline for intermittent claudication

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 10, 2020, Pages

  Broderick, Cathryn ^a   Forster, Rachel ^a   Abdel Hadi, Mohammed ^b   Salhiyyah, Kareem ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Department of Cardiac and Vascular Surgery   (Germany)

^c MIDDLE EAST UNIVERSITY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BUFLOMEDIL; BUPHENINE; FLUNARIZINE; GINKGO BILOBA EXTRACT; NIFEDIPINE; PENTOXIFYLLINE; PLACEBO; PROSTAGLANDIN E1; ANTITHROMBOCYTIC AGENT; VASODILATOR AGENT;

ANKLE BRACHIAL INDEX; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EUROPE; EXERCISE; HUMAN; INTERMITTENT CLAUDICATION; NAUSEA; PAIN FREE WALKING DISTANCE; PHARMACOLOGICAL PARAMETERS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TOTAL WALKING DISTANCE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; WALKING DISTANCE; META ANALYSIS; WALKING;

ANKLE BRACHIAL INDEX; HUMANS; INTERMITTENT CLAUDICATION; PENTOXIFYLLINE; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS; WALKING;

EID: 85093491802     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005262.pub4     Document Type: Review

References (118)

1. Accetto B. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin. American Heart Journal 1982;103(5):864-9. x-wiley/crsRef/3198068
2. Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Cesarone MR, Incandela L, et al. Intermittent claudication in diabetics: treatment with exercise and pentoxifylline – a 6-month, controlled, randomized trial. Angiology 2002;53 Suppl 1:39-43. x-wiley/crsRef/3198070
3. Bohmer D, Kalinski S, Michaelis P, Szogy A. Efficacy and tolerance of Ginkgo biloba extract compared to that of pentoxifylline in the treatment of patients suffering from peripheral chronic arterial occlusive disease. Hers Kreislauf 1988;20(1):5-8. x-wiley/crsRef/3198072
4. Bollinger A, Frei CH. Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1977;1(9):557-62. x-wiley/crsRef/3198074
5. Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Incandela L, et al. Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial. Angiology 2002;53 Suppl 1:1-5. x-wiley/crsRef/14723646
6. Chacon-Quevedo A, Eguaras MG, Calleja F, Garcia MA, Roman M, Casares J, et al. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs. Angiology 1994;45(7):647-53. x-wiley/crsRef/3198078
7. Ciocon JO, Galindo-Ciocon D, Galindo DJ. A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly. Angiology 1997;48(3):237-40. x-wiley/crsRef/3198080
8. Creager MA, Pande RL, Hiatt WR. A randomized trial of iloprost in patients with intermittent claudication. Vascular Medicine 2008;13(1):5-13. x-wiley/crsRef/3198082
9. Dawson DL, Beebe HG, Herd JA, Chinoy DA, Davidson MH, Hiatt WR, et al. Cilostozol or pentoxifylline for claudication. Circulation 1998;98 Suppl 1:1-12. x-wiley/crsRef/3198084
10. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine 2000;109(7):523-30. x-wiley/crsRef/3198085
11. Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV Jr. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 2002;53(5):509-20. x-wiley/crsRef/3198086
12. De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Incandela L, et al. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial – walking distance and microcirculation. Angiology 2002;53 Suppl 1:7-12. x-wiley/crsRef/3198088
13. De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Incandela L, et al. Treatment of long-distance intermittent claudication with pentoxifylline: a 12-month, randomized trial. Angiology 2002;53 Suppl 1:13-7. x-wiley/crsRef/3198090
14. Di Perri T, Guerrini M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology 1983;34(1):40-5. x-wiley/crsRef/3198092
15. Donaldson DR, Hall TJ, Kester RC, Ramsden CW, Wiggins PA. Does oxpentifylline ('Trental') have a place in the treatment of intermittent claudication? Current Medical Research and Opinion 1984;9(1):35-40. x-wiley/crsRef/3198094
16. Donaldson DR, Kester RC, Russell CW, Wiggins PA, Hall TJ. Does oxpentifylline (Trental) have a place in the treatment of intermittent claudication? Clinical Hemorheology 1981;1(5-6):469. x-wiley/crsRef/3198095
17. Ernst E, Kollar L, Resch KL. Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology 1992;43(2):121-5. x-wiley/crsRef/3198097
18. Gallus AS, Gleadow F, Dupont P, Walsh J, Morley AA, Wenzel A, et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Australian and New Zealand Journal of Medicine 1985;15(4):402-9. x-wiley/crsRef/3198099
19. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Clinical comparison of the effect of I.U. prostaglandin E1 and I.U. pentoxifylline in patients with arterial occlusive disease [Vergleich der klinischen wirksamkeit von i.v. prostaglandin E1 und i.v. pentoxifyllin bei patienten mit arterieller verschlubkrankheit im stadium llb nach fontaine]. VASA 1992;21(4):447 Abstract No. 6.3. x-wiley/crsRef/3198101
20. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Intravenous prostaglandin E1 versus pentoxifylline: a randomized controlled study in patients with intermittent claudication. International Angiology 1995;14 Suppl 1:280. x-wiley/crsRef/3198102
21. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Therapeutic effectiveness of PGE1 intravenous administered comparising with pentoxifylline on intermittent claudication [Therapeutische wirksamheit von intravenos verabreichtem PGE1 in vergleich mit pentoxifyllin bei claudicatio intermittens]. ANGIO 1992;14(2):59-64. x-wiley/crsRef/3198103
22. Hepp W, von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Randomized study comparing the clinical effectiveness of intravenous prostaglandin E1 and intravenous pentoxifylline in patients with Fontaine stage IIb arterial occlusive disease [Randomisierte studie zum vergleich der klinischen wirksamkeit von i.v. prostaglandin E1 and i.v. pentoxifyllin bei patienten mit arterieller verschlubkrankheit im stadium IIb nach fontaine]. VASA. Supplementum 1991;33:348-9. x-wiley/crsRef/3198104
23. Kiesewetter H, Blume J, Jung F, Waldhausen P, Gerhards M. Intermittent claudication. Increase in walking distance and improvement of hemorheologic parameters by pentoxifylline (Trental 400). MMW, Munchener Medizinische Wochenschrift 1988;130:357-60. x-wiley/crsRef/3198106
24. Lee TM, Su SF, Hwang JJ, Tseng CD, Chen MF, Lee YT, et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis 2001;158(2):471-6. x-wiley/crsRef/14723648
25. Lee TM, Su SF, Tsai CH, Lee YT, Wang SS. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clinical Science 2001;101(3):305-11. x-wiley/crsRef/14723649
26. Lindgarde F, Jelnes R, Bjorkman H, Adielsson G, Kjellstrom T, Palmquist I, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989;80(6):1549-56. x-wiley/crsRef/3198111
27. Perhoniemi V, Salmenkivi K, Sundberg S, Johnsson R, Gordin A. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication. Angiology 1984;35(6):366-72. x-wiley/crsRef/3198113
28. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. Journal of Clinical Pharmacology 1987;27(8):601-9. x-wiley/crsRef/3198115
29. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. American Heart Journal 1982;104(1):66-72. x-wiley/crsRef/3198116
30. Reich T, Cutler BC, Lee BY, Porter JM, Reichle FA, Scogin JT, et al. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Angiology 1984;35(7):389-95. x-wiley/crsRef/3198117
31. Reich T, Gillings D. Effects of pentoxifylline on severe intermittent claudication. Angiology 1987;38(9):651-6. x-wiley/crsRef/3198118
32. Porter JM, Bauer GM. Pharmacologic treatment of intermittent claudication. Surgery 1982;92(6):966-71. x-wiley/crsRef/3198120
33. NCT01263925. Prostaglandin E1 in outpatients with intermittent claudication. clinicaltrials.gov/ct2/show/NCT01263925 (first received 21 December 2010). x-wiley/crsRef/3198122
34. Schellong S, Baron Von Bilderling P, Grus JD, Lawall H, Grieger F, Ney U, et al. Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication: results of a clinical study. VASA 2012;41(Suppl 82):78. x-wiley/crsRef/14723650
35. Schellong SM, von Bilderling P, Gruss JD, Lawall H, Grieger F, Ney U, et al. Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication: results of a randomised clinical trial. VASA 2017;46(5):403-5. x-wiley/crsRef/14723651
36. Volker D. Treatment of arterial diseases with Trental 400. Results of a double-blind study. Die Medizinische Welt 1978;29(32):1244-7. x-wiley/crsRef/3198125
37. Bieron K, Kostka-Trabka E, Starzyk D, Goszcz A, Grodzinska L, Korbut R. Bencyclane – a new aspect of the mechanism of action in patients with peripheral arterial occlusive disease. Open-label, prospective, randomized trial. Acta Angiologica 2005;11(3):157-72. x-wiley/crsRef/3198127
38. Ciuffetti G, Mercuri M, Ott C, Lombardini R, Paltriccia R, Lupattelli G, et al. Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study. European Journal of Clinical Pharmacology 1991;41(6):511-5. x-wiley/crsRef/3198129
39. Dawson DL, DeMaioribus CA, Hagino RT, Light JT, Bradley DV Jr, Britt KE, et al. The effect of withdrawal of drugs treating intermittent claudication. American Journal of Surgery 1999;178(2):141-6. x-wiley/crsRef/3198131
40. Dettori AG, Pini M, Moratti A, Paolicelli M, Basevi P, Quintavalla R, et al. Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group. Angiology 1989;40(4 part 1):237-48. x-wiley/crsRef/3198133
41. Ehrly AM, Saeger-Lorenz K. Effect of pentoxifylline on the muscle tissue oxygen pressure of claudicants after pedoergometric exercise. Angiology 1986;37(5):398. x-wiley/crsRef/3198135
42. Ehrly AM, Saeger-Lorenz K. Influence of pentoxifylline on muscle tissue oxygen tension (pO2) of patients with intermittent claudication before and after pedal ergometer exercise. Angiology 1987;38(2 part 1):93-100. x-wiley/crsRef/3198137
43. Farkas K, Horvath P, Farsang C. Pentoxifylline treatment of patients with peripheral obstructive vascular disease. International Angiology 1993;12:64. x-wiley/crsRef/3198139
44. Fossat C, Fabre D, Alimi Y, Bienvenu J, Aillaud MF, Lenoble M, et al. Leukocyte activation study during occlusive arterial disease of the lower limb: effect of pentoxifylline infusion. Journal of Cardiovascular Pharmacology 1995;25 Suppl 2:96-100. x-wiley/crsRef/3198141
45. Geppert T, Kirchhof C, Schmidt-Lucke C, Schmidt-Lucke A. Superior therapeutic effect of intermittent vasodilator infusion therapy on walking distance among patients with peripheral arterial disease and intermittent claudication. VASA 2017;46(Suppl 97):29. x-wiley/crsRef/14723653
46. Guest JF, Davie AM, Clegg JP. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. Current Medical Research and Opinion 2005;21(6):817-26. x-wiley/crsRef/3198143
47. Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E, Rudofsky G, et al. Clinical efficacy of IV prostaglandin E1 and IV pentoxifylline in patients with arterial occlusive disease of fontaine stage IIb: a multicenter, randomized comparative study. International Journal of Angiology 1996;5(1):32-7. x-wiley/crsRef/3198145
48. Horowitz I. Results of a multicenter randomised double blind study. Pentoxyifylline versus placebo for 6 months on lower limb artertiopathies [Resultats d'une etude multicentrique randomisee en double aveugle. Pentoxifylline contre placebo prolongee sur 6 mois dans les arteriopathies des membres inferieurs]. Actualities D'Angiologie 1982;7:31-4. x-wiley/crsRef/3198147
49. Incandela L, De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Geroulakos G, et al. Short-range intermittent claudication and rest pain: microcirculatory effects of pentoxifylline in a randomized, controlled trial. Angiology 2002;53 Suppl 1:27-30. x-wiley/crsRef/3198149
50. Kellner H. Treatment of chronic arterial circulatory disorders. Double blind trial with Trental 400. MMW, Munchener Medizinische Wochenschrift 1976;118(43):1399-402. x-wiley/crsRef/3198151
51. Luk'Janov Y. Hemorheologic and hemodynamic changes after treatments with PGE versus pentoxifylline (PF) in patients with peripheral arterial disease (PAD). International Angiology 1995;14 Suppl 1:372. x-wiley/crsRef/3198153
52. Milio G, Cospite V, Cospite M. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease. Minerva Cardioangiologica 2003;51(3):311-6. x-wiley/crsRef/3198155
53. Milio G, Coppola G, Novo S. The effects of prostaglandin E-1 in patients with intermittent claudication. Cardiovascular & Hematological Disorders Drug Targets 2006;6(2):71-6. x-wiley/crsRef/3198157
54. Panchenko E, Eshkeeva A, Dobrovolsky A, Titaeva E, Podinovskaya Y, Hussain KM, et al. Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: results of six months treatment. Angiology 1997;48(3):247-54. x-wiley/crsRef/3198159
55. Pignoli P, Ciccolo F, Villa V, Longo T. Comparative evaluation of buflomedil and pentoxifylline in patients with peripheral arterial occlusive disease. Current Therapeutic Research 1985;37(4):596-606. x-wiley/crsRef/3198161
56. Poggesi L, Scarti L, Boddi M, Masotti G, Serneri GG. Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis. Angiology 1985;36(9):628-37. x-wiley/crsRef/3198163
57. Regenthal R, Voigt H, Reuter W, Preiss R. The effect of oral trapidil therapy on clinical and hemorheological parameters in arteriosclerosis obliterans in comparison to pentoxifylline – a pilot study. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1991;46(6):185-90. x-wiley/crsRef/3198165
58. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. New Zealand Medical Journal 1987;100(828):445-7. x-wiley/crsRef/3198167
59. Rodin SM. Pletal (cilostazol) tablets. Center for Drug Evaluation and Research. Application number: NDA 20-863, 1998;Study 21-96-202:27-40. x-wiley/crsRef/14723655
60. Rodin SM. Pletal (cilostazol) tablets. Center for Drug Evaluation and Research. Application number: NDA 20-863 Otsuka America, 1998;Study 21-94-301:58-72. x-wiley/crsRef/14723657
61. Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 1984;35(7):396-406. x-wiley/crsRef/3198173
62. Rudofsky G, Haussler KF, Kunkel HP, Schneider-May H, Spengel F, Symann O, et al. Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental – results of a multicenter double-blind study [Zur wirksamkeit einer intravenosen infusionbehandlung der peripheren arteriellen verschlubkrankheit mit Trental – Ergebnisse einer multi-zentrischen doppelblindstudie]. VASA. Supplementum 1987;20:375-8. x-wiley/crsRef/3198175
63. Rudofsky G, Haussler KF, Kunkel HP, Schneider-May H, Spengel F, Symann O, et al. Intravenous pentoxifylline treatment in chronic peripheral arterial disease. Die Medizinische Welt 1988;39(39):1136-40. x-wiley/crsRef/3198177
64. Rudofsky G, Haussler KF, Kunkel HP, Schneider-May H, Spengel F, Symann O, et al. Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. Angiology 1989;40(7):639-49. x-wiley/crsRef/3198179
65. Scheffler P, de la Hamette D, Muller H. Controlled vascular training in IIb peripheral arterial occlusive disease: additive effect of intravenous PGE1 versus intravenous pentoxifylline during training. VASA. Supplementum 1991;33:350-2. x-wiley/crsRef/3198181
66. Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994;90(2):818-22. x-wiley/crsRef/3198183
67. Schubotz R. Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders. Pharmatherapeutica 1976;1(3):172-9. x-wiley/crsRef/3198185
68. Shustov SB, Canova N. Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease. Current Medical Research and Opinion 1997;13(10):573-82. x-wiley/crsRef/3198187
69. Singh S, Singh H, Kohli A, Kapoor V, Singh G. Effects of cilostazole and pentoxifylline on claudication distance and lipid profile in patients with occlusive peripheral arterial disease: a comparative trial. Indian Journal of Thoracic Cardiovascular Surgery 2009;25:45-8. x-wiley/crsRef/3198189
70. Skovborg F, Bonde-Petersen F, Bloch I, Christensen E. Intermittent claudication treated with pentoxyphylline. A controlled trial [Claudicatio intermittens behandlet med pentoksyfyllin]. Ugeskrift for laeger 1983;145(47):3649-52. x-wiley/crsRef/14723659
71. Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984;35(7):459-66. x-wiley/crsRef/3198191
72. Strano A. Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. Clinical Drug Investigation 2002;22 Suppl 1:1-6. x-wiley/crsRef/3198193
73. Thomson GJ, Thomson S, Todd AS, Vohra RK, Carr MH, Walker MG. Combined intravenous and oral pentoxifylline in the treatment of peripheral vascular disease. A clinical trial. International Angiology 1990;9(4):266-70. x-wiley/crsRef/3198195
74. Tonak J, Knecht H, Groitl H. Treatment of circulation disorders with pentoxifylline. A double-blind study with Trental [Zur behandlung von durchblutungsstorungen mit pentoxifyllin. Eine doppelblindstudie mit trental]. Medizinische Monatsschrift 1977;31(10):467-72. x-wiley/crsRef/3198197
75. Triebe G, Munnich U, Liebold F. A therapeutic comparison between hemodilution and pentoxifylline in arterial obstructive disease. An objective assessment by quantitative Doppler sonography. Deutsche Medizinische Wochenschrift 1992;117(14):523-30. x-wiley/crsRef/3198199
76. Tsang GM, Sanghera K, Gosling P, Smith FC, Paterson IS, Simms MH, et al. Pharmacological reduction of the systemically damaging effects of local ischaemia. European Journal of Vascular Surgery 1994;8(2):205-8. x-wiley/crsRef/3198201
77. Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 2003;171(2):337-42. x-wiley/crsRef/3198203
78. Bachoo P, Thorpe PA, Maxwell H, Welch K. Endovascular stents for intermittent claudication. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD003228. [DOI: 10.1002/14651858.CD003228.pub2]
79. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No: CD003748. [DOI: 10.1002/14651858.CD003748.pub4]
80. Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV Jr. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 2002;53(5):509-20.
81. de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No: CD001368. [DOI: 10.1002/14651858.CD001368.pub4]
82. de Backer TL, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No: CD000988. [DOI: 10.1002/14651858.CD000988.pub4]
83. Ernst E. Pentoxifylline for intermittent claudication. A critical review. Angiology 1994;45(5):339-45.
84. Aboyans V, Ricco JB, Bartelink ML, Björck M, Brodmann M, Cohnert T, ESC Scientific Document Group, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. European Heart Journal 2018;39(9):763-816. [DOI: 10.1093/eurheartj/ehx095]
85. PAD Guideline Writing Group. European Society for Vascular Medicine (ESVM) – guideline on peripheral arterial disease. VASA 2019;48(Suppl 102):1-79. [DOI: 10.1024/0301-1526/a000834]
86. Fontaine VR, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders [Die chirurgische Behandlung der peripheren Durchblutungsstörungen]. Helvetica Chirurgica Acta 1954;21(5-6):499-533.
87. Fowkes G, Gillespie IN. Angioplasty (versus non surgical management) for intermittent claudication. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No: CD000017. [DOI: 10.1002/14651858.CD000017]
88. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382(9901):1329-40.
89. Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs & Aging 1995;7(6):480-503.
90. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. Journal of Clinical Pharmacology 1987;27(8):601-9.
91. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
92. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No: CD000990. [DOI: 10.1002/14651858.CD000990.pub4]
93. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane reviews. Systematic Reviews 2013;2:81. [DOI: 10.1186/2046-4053-2-81]
94. Lee TM, Su SF, Hwang JJ, Tseng CD, Chen MF, Lee YT, et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis 2001;158(2):471-6.
95. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
96. Marshall IJ, Noel-Storr AH, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods 2018;9(4):602-14.
97. McDonald S, Noel-Storr AH, Thomas J. Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. Global Evidence Summit; 2017 Sept 13-16; Cape Town, South Africa.
98. Medline Plus. Pentoxifylline. https://medlineplus.gov/druginfo/meds/a685027.html (accessed 17 September 2020).
99. Meijer WT, Cost B, Bernsen RM, Hoes AW. Incidence and management of intermittent claudication in primary care in The Netherlands. Scandinavian Journal of Primary Health Care 2002;20(1):33-4.
100. Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology 2014;65(3):190-7.
101. ® Healthcare Series. lrs.lendac.ie/m&p.html (accessed for original version 2011, no longer available).
102. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000;59(5):1057-70.
103. National Institute for Health and Care Excellence (NICE). Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. www.nice.org.uk/ guidance/TA223/chapter/2-Clinical-need-and-practice (accessed 5 April 2015).
104. National Institute for Health and Care Excellence (NICE). Lower limb peripheral arterial disease: diagnosis and management. www.nice.org.uk/Guidance/CG147 (accessed 5 April 2015).
105. Noel-Storr AH, the Project Transform team. Cochrane Crowd: new ways of working together to produce health evidence. Evidence Live 2018; 2018 Jun 18-20; Oxford (UK).
106. Reich T, Cutler BC, Lee BY, Porter JM, Reichle FA, Scogin JT, et al. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Angiology 1984;35(7):389-95.
107. Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No: CD000986. [DOI: 10.1002/14651858.CD000986.pub3]
108. Sanofi. Pentoxifylline. medicines.org.uk/emc/medicine/338/SPC/Trental+400/#PHARMACEUTICAL_PARTS (accessed 17 September 2020).
109. Schellong SM, von Bilderling P, Gruss JD, Lawall H, Grieger F, Ney U, et al. Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication: results of a randomised clinical trial. VASA 2017;46(5):403-5.
110. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for intermittent claudication in people with peripheral arterial disease. Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Clinical Excellence 2010.
111. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technology Assessment 2011;15(40):1-210.
112. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery 2012;99(12):1630-8.
113. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clement D, Collet J-P, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. European Heart Journal 2011;32:2851-906.
114. Thomas J, Noel-Storr AH, Marshall I, Wallace B, McDonald S, Mavergames C, et al. Living systematic review network. Living systematic reviews: 2. Combining human and machine effort. Journal of Clinical Epidemiology 2017;91:31-7.
115. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No: CD001272. [DOI: 10.1002/14651858.CD001272]
116. Salhiyyah K, Palfreyman SS, Booth A, Michaels JA, Senanayake E. Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No: CD005262. [DOI: 10.1002/14651858.CD005262]
117. Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No: CD005262. [DOI: 10.1002/14651858.CD005262.pub2]
118. Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD005262. [DOI: 10.1002/14651858.CD005262.pub3]